Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Pulmonology (COPD, asthma, interstitial lung disease). These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG Question 1: A 56-year-old man presents with progressive dyspnea and dry cough. HRCT shows honeycombing and traction bronchiectasis in lower lobes. He has clubbing. What is the most likely diagnosis?
- A. COPD
- B. Asthma
- C. Idiopathic pulmonary fibrosis (Correct Answer)
- D. Sarcoidosis
- E. Hypersensitivity pneumonitis
Pulmonology (COPD, asthma, interstitial lung disease) Explanation: ***Idiopathic pulmonary fibrosis***- The clinical presentation of **progressive dyspnea**, **dry cough**, and **clubbing** in an older patient, coupled with HRCT findings of **honeycombing** and **traction bronchiectasis** predominantly in the **lower lobes**, are classic features of **Usual Interstitial Pneumonia (UIP)** pattern, diagnostic of IPF.- **UIP** pattern on HRCT signifies extensive subpleural and basilar fibrosis with architectural distortion, where **honeycombing** represents clustered cystic airspaces and **traction bronchiectasis** indicates bronchial dilation due to surrounding fibrotic retraction.*COPD*- **COPD** is characterized by persistent **airflow limitation**, often with a history of smoking and a productive cough, contrasting with the dry cough and restrictive pattern of fibrosis seen here.- HRCT in COPD typically shows **emphysema** (centrilobular or panlobular) or **airway wall thickening**, but not the **honeycombing** and **traction bronchiectasis** indicative of severe pulmonary fibrosis.*Asthma*- **Asthma** is an inflammatory airway disease marked by **reversible airflow obstruction** and bronchial hyperresponsiveness, presenting with episodic wheezing, chest tightness, and dyspnea, which usually respond to bronchodilators.- HRCT in asthma may show **bronchial wall thickening** or **air trapping**, but it does not exhibit the progressive fibrotic changes like **honeycombing** or **traction bronchiectasis** seen in this patient.*Sarcoidosis*- **Sarcoidosis** is a multisystem granulomatous disease, often involving the lungs with **bilateral hilar lymphadenopathy** and a **perilymphatic distribution** of nodules, typically in the upper and mid lung zones.- While sarcoidosis can cause fibrosis (Stage 4), it typically manifests as **upper lobe predominant fibrosis** with conglomerate masses and volume loss, rather than the lower lobe predilection and characteristic UIP pattern.*Hypersensitivity pneumonitis*- Chronic **hypersensitivity pneumonitis (HP)** can lead to fibrosis, but HRCT often reveals a mosaic attenuation pattern, **centrilobular nodules**, and **air trapping**, with fibrosis potentially sparing the subpleural regions.- Although HP can mimic a UIP pattern in some cases, the classic presentation of progressive dyspnea, dry cough, clubbing, and strict lower lobe **honeycombing** and **traction bronchiectasis** points more strongly to IPF.
Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG Question 2: A patient presents with respiratory difficulty and a history of chronic smoking. Pulmonary function testing shows a decrease in FEV1/FVC ratio. What is the most probable diagnosis?
- A. Interstitial Lung Disease
- B. Pulmonary Fibrosis
- C. Asthma
- D. Chronic Obstructive Pulmonary Disease (COPD) (Correct Answer)
Pulmonology (COPD, asthma, interstitial lung disease) Explanation: ***Chronic Obstructive Pulmonary Disease (COPD)***
- COPD is the most likely diagnosis given the history of **chronic smoking** and pulmonary function tests showing a **decreased FEV1%**, which is a hallmark of an **obstructive lung disease**.
- The pathophysiology involves **bronchiolar obstruction** leading to **air trapping**, which results in an elevated **Residual Volume (RV)** and **Total Lung Capacity (TLC)**, consistent with the provided flowchart.
*Pulmonary Fibrosis*
- This is a **restrictive lung disease**, characterized by scarring of the lung tissue, which would cause a **decrease**, not an increase, in Total Lung Capacity (TLC).
- Spirometry in pulmonary fibrosis typically shows a **normal or increased FEV1/FVC ratio**, as both FEV1 and FVC are reduced proportionally.
*Interstitial Lung Disease*
- This is a broad category of **restrictive lung diseases**, which includes pulmonary fibrosis. These conditions make the lungs stiff and difficult to expand.
- The characteristic PFT finding is a **restrictive pattern** (decreased TLC, FVC, and FEV1) with a normal or high FEV1/FVC ratio, which contradicts the patient's results.
*Asthma*
- Although asthma is an **obstructive disease** that can cause a low FEV1%, the airflow limitation is typically **reversible** with bronchodilators.
- While both can present similarly, the patient's history of **chronic smoking** makes COPD, a progressive and largely irreversible condition, the more probable diagnosis.
Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG Question 3: Which of the following is/are characteristic pathological findings in asthma?
- A. Curschmann spirals
- B. Charcot-Leyden crystals
- C. Occlusion of bronchi and bronchioles by mucus
- D. All of the options (Correct Answer)
Pulmonology (COPD, asthma, interstitial lung disease) Explanation: ***All of the above***
- Asthma is associated with various pathological findings, including **Charcot-Leyden crystals** and **Curschmann spirals** during bronchial inflammation [1].
- These findings represent the underlying **eosinophilic** and **mucous** hypersecretion processes commonly seen in asthma [2,3].
*Charcot-Leyden crystals*
- These **crystals** are associated with **eosinophilic** inflammation, but their presence alone is not definitive for asthma diagnosis [2].
- They are often found in **sputum** of asthmatic patients but are not the only indicator of asthma presence.
*Curschmann spirals*
- These **spirals** indicate **mucous plugging** of bronchi and are indeed seen in asthma, but signify only one aspect of the condition [1,3].
- They highlight the **mucosal** response in asthma rather than providing a comprehensive view of the disease.
*Occlusion of bronchi and bronchioles by mucus*
- **Mucus** production leading to **bronchial obstruction** occurs in asthma, but this statement is too narrow to encompass the condition's entirety [1].
- While it is a common feature, it does not consider the immunological or inflammatory elements intrinsic to asthma.
**References:**
[1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Respiratory Tract Disease, pp. 328-329.
[2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 688-689.
[3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Respiratory Tract Disease, pp. 329-330.
Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG Question 4: A 32-year-old woman presents to the Emergency Department with an acute asthma exacerbation. She receives nebulised salbutamol 5mg and ipratropium 500 micrograms with oxygen, oral prednisolone 40mg, and controlled oxygen therapy. Initial peak flow was 30% of her best. After 1 hour of treatment, repeat observations show: heart rate 128 bpm, respiratory rate 30 breaths/min, oxygen saturation 91% on 40% oxygen, peak flow 32% of best. She appears exhausted and is speaking in words only. Arterial blood gas shows: pH 7.28, PaCO2 6.8 kPa, PaO2 8.1 kPa, HCO3- 24 mmol/L on 40% oxygen. What is the most critical next step in management?
- A. Commence intravenous magnesium sulphate 2g over 20 minutes
- B. Start intravenous aminophylline infusion
- C. Repeat nebulised bronchodilators continuously
- D. Involve senior medical staff and ICU team immediately (Correct Answer)
- E. Arrange transfer to high dependency unit for non-invasive ventilation
Pulmonology (COPD, asthma, interstitial lung disease) Explanation: ***Involve senior medical staff and ICU team immediately***
- The patient exhibits features of **near-fatal asthma**, specifically a **raised PaCO2 (6.8 kPa)** and respiratory **acidosis (pH 7.28)**, which indicate respiratory muscle fatigue and impending ventilatory failure.
- Clinical signs of **exhaustion**, inability to speak in full sentences, and persistent **hypoxia (SaO2 91% on 40% O2)** despite initial therapy necessitate immediate escalation for potential **intubation and mechanical ventilation**.
*Commence intravenous magnesium sulphate 2g over 20 minutes*
- While **IV magnesium** is indicated in life-threatening asthma not responding to initial treatment, it is an adjunctive therapy and should not delay immediate senior/ICU involvement given the critical ABG results.
- In the presence of **hypercapnia** and exhaustion, pharmacological bronchodilation alone is unlikely to prevent the need for more advanced respiratory support.
*Start intravenous aminophylline infusion*
- **Aminophylline** is a second-line bronchodilator used in severe exacerbations but has a narrow therapeutic index and requires careful monitoring.
- It is less effective than other therapies and does not address the immediate life-threatening risk of **respiratory arrest** or the need for ventilatory support seen in this patient.
*Repeat nebulised bronchodilators continuously*
- Continuous **nebulised beta-agonists** are standard for poor initial response, but they have already failed to significantly improve the patient's **peak flow (only 32%)** and clinical status after 1 hour.
- Relying solely on nebulizers in the setting of a **rising PaCO2** and clinical exhaustion is dangerous as it ignores the physiological signs of **ventilatory failure**.
*Arrange transfer to high dependency unit for non-invasive ventilation*
- **Non-invasive ventilation (NIV)** is generally **not recommended** in acute severe asthma as it can delay necessary **endotracheal intubation** and may exacerbate dynamic hyperinflation.
- Transfer to a High Dependency Unit (HDU) is insufficient; the severity of near-fatal asthma requires the full capabilities of an **Intensive Care Unit (ICU)** for invasive monitoring and ventilation.
Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG Question 5: A 35-year-old pregnant woman at 24 weeks gestation with moderate persistent asthma presents with worsening symptoms over 3 days. She has been using albuterol 6-8 times daily. She discontinued her ICS/LABA inhaler when she learned she was pregnant due to concerns about fetal safety. Current medications include prenatal vitamins only. Vital signs: respiratory rate 24/min, oxygen saturation 94% on room air, heart rate 98/min. Peak flow is 60% of her personal best. Fetal heart monitoring is reassuring. Synthesizing the management approach that balances maternal asthma control and fetal safety, what is the most appropriate treatment plan?
- A. Continue albuterol only until delivery to minimize fetal medication exposure
- B. Start oral prednisone and continue albuterol only
- C. Restart ICS/LABA, give oral prednisone burst, close monitoring (Correct Answer)
- D. Give IM corticosteroids and restart ICS after delivery
- E. Hospitalize for IV corticosteroids and continuous monitoring
Pulmonology (COPD, asthma, interstitial lung disease) Explanation: ***Restart ICS/LABA, give oral prednisone burst, close monitoring***
- For a patient with **moderate persistent asthma** experiencing an exacerbation, an **oral corticosteroid burst** is necessary to reduce inflammation, while **ICS/LABA** must be resumed to provide long-term control.
- Maintaining maternal asthma control is vital for preventing **fetal hypoxia**; the risks of uncontrolled asthma to the fetus far outweigh the potential risks of these medications.
*Continue albuterol only until delivery to minimize fetal medication exposure*
- Relying solely on a **SABA** for persistent asthma is dangerous and increases the risk of **preterm birth**, **low birth weight**, and maternal respiratory failure.
- **Suboptimal control** of asthma during pregnancy is more harmful to the fetus than the medications used to manage it.
*Hospitalize for IV corticosteroids and continuous monitoring*
- The patient’s oxygen saturation (94%) and **peak flow (60%)** indicate a moderate exacerbation that can typically be managed in the **outpatient setting** with close follow-up.
- Hospitalization is reserved for those with **severe respiratory distress**, failed outpatient therapy, or signs of **fetal compromise**.
*Start oral prednisone and continue albuterol only*
- While prednisone clears the acute flare, failing to restart maintenance **controller therapy** (ICS/LABA) will likely lead to another exacerbation as soon as the steroid burst ends.
- Chronic airway inflammation in **moderate persistent asthma** requires daily preventive treatment, not just episodic rescue medication.
*Give IM corticosteroids and restart ICS after delivery*
- **IM corticosteroids** are not the standard of care for acute asthma flares; **oral prednisone** is preferred for its predictable absorption and efficacy.
- Delaying the resumption of controller therapy until **after delivery** leaves the mother and fetus at high risk during the remainder of the pregnancy.
More Pulmonology (COPD, asthma, interstitial lung disease) US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
